📊 MRVI Key Takeaways
Is MRVI a Good Investment? Thesis Analysis
Maravai LifeSciences is experiencing severe operational distress with negative operating income of -$215.3M despite $185.7M in revenue, indicating fundamental business model challenges. The company is burning cash with -$70.7M free cash flow and negative operating cash flow, while carrying substantial debt of $291.8M against only $212.4M in equity, creating financial vulnerability.
Why Buy MRVI? Key Strengths
- Strong liquidity position with $216.9M in cash and 6.60x current ratio providing near-term financial flexibility
- Gross margin of 18.3% indicates some ability to generate contribution margin on revenue
- Sufficient cash balance to sustain operations for approximately 3-4 quarters at current burn rate
MRVI Investment Risks to Consider
- Severe operating losses with -115.9% operating margin and -70.4% net margin indicate the business is unprofitable at scale
- Negative free cash flow of -$70.7M combined with high debt load (1.37x debt-to-equity) creates unsustainable capital structure
- Revenue declined 28.3% year-over-year signaling demand deterioration and inability to maintain market position
- Negative interest coverage of -5.9x means operating income cannot service debt obligations, requiring asset sales or restructuring
- Operating cash flow negative at -$57.6M indicates cash burn independent of non-cash charges
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Revenue stabilization and return to growth trajectory
- Operating income improvement and achievement of positive EBITDA
- Debt reduction progress and refinancing strategy given covenant pressures
- Cash burn rate and runway remaining before liquidity crisis
MRVI Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.60x current ratio provides a solid financial cushion.
MRVI Profitability Ratios
MRVI vs Healthcare Sector
How MARAVAI LIFESCIENCES HOLDINGS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MRVI Overvalued or Undervalued?
Based on fundamental analysis, MARAVAI LIFESCIENCES HOLDINGS, INC. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MRVI Balance Sheet & Liquidity
MRVI 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MARAVAI LIFESCIENCES HOLDINGS, INC.'s revenue has declined by 64% over the 5-year period, indicating business contraction. The most recent EPS of $-0.90 indicates the company is currently unprofitable.
MRVI Growth Metrics (YoY)
MRVI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $41.6M | -$25.6M | $-0.18 |
| Q2 2025 | $47.4M | -$9.8M | $-0.07 |
| Q1 2025 | $46.9M | -$12.1M | $-0.09 |
| Q3 2024 | $65.2M | -$6.5M | $-0.05 |
| Q2 2024 | $68.9M | -$6.5M | $-0.05 |
| Q1 2024 | $64.2M | -$67.0K | $0.00 |
| Q3 2023 | $66.9M | -$6.5M | $-0.05 |
| Q2 2023 | $68.9M | -$6.5M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MRVI Capital Allocation
MRVI SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MARAVAI LIFESCIENCES HOLDINGS, INC. (CIK: 0001823239)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRVI
What is the AI rating for MRVI?
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRVI's key strengths?
Claude: Strong liquidity position with $216.9M in cash and 6.60x current ratio providing near-term financial flexibility. Gross margin of 18.3% indicates some ability to generate contribution margin on revenue.
What are the risks of investing in MRVI?
Claude: Severe operating losses with -115.9% operating margin and -70.4% net margin indicate the business is unprofitable at scale. Negative free cash flow of -$70.7M combined with high debt load (1.37x debt-to-equity) creates unsustainable capital structure.
What is MRVI's revenue and growth?
MARAVAI LIFESCIENCES HOLDINGS, INC. reported revenue of $185.7M.
Does MRVI pay dividends?
MARAVAI LIFESCIENCES HOLDINGS, INC. does not currently pay dividends.
Where can I find MRVI SEC filings?
Official SEC filings for MARAVAI LIFESCIENCES HOLDINGS, INC. (CIK: 0001823239) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRVI's EPS?
MARAVAI LIFESCIENCES HOLDINGS, INC. has a diluted EPS of $-0.90.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRVI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MARAVAI LIFESCIENCES HOLDINGS, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MRVI stock overvalued or undervalued?
Valuation metrics for MRVI: ROE of -61.6% (sector avg: 15%), net margin of -70.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MRVI stock in 2026?
Our dual AI analysis gives MARAVAI LIFESCIENCES HOLDINGS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRVI's free cash flow?
MARAVAI LIFESCIENCES HOLDINGS, INC.'s operating cash flow is $-57.6M, with capital expenditures of $13.1M. FCF margin is -38.1%.
How does MRVI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -70.4% (avg: 12%), ROE -61.6% (avg: 15%), current ratio 6.60 (avg: 2).